Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9364 |
High Similarity |
NPD228 |
Approved |
0.9016 |
High Similarity |
NPD3027 |
Phase 3 |
0.8504 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8504 |
High Similarity |
NPD1613 |
Approved |
0.8417 |
Intermediate Similarity |
NPD1357 |
Approved |
0.8226 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.822 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8189 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.811 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8103 |
Intermediate Similarity |
NPD2684 |
Approved |
0.8077 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.8077 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.8077 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.8065 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8017 |
Intermediate Similarity |
NPD290 |
Approved |
0.8 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7983 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7969 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7934 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7895 |
Intermediate Similarity |
NPD291 |
Approved |
0.7881 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7881 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7868 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7863 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7795 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7795 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.776 |
Intermediate Similarity |
NPD9381 |
Approved |
0.776 |
Intermediate Similarity |
NPD9384 |
Approved |
0.7737 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7737 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7717 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7661 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7656 |
Intermediate Similarity |
NPD9622 |
Approved |
0.7652 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7652 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7638 |
Intermediate Similarity |
NPD1091 |
Approved |
0.76 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7594 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7591 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7557 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7552 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7521 |
Intermediate Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7481 |
Intermediate Similarity |
NPD9619 |
Approved |
0.7481 |
Intermediate Similarity |
NPD9620 |
Approved |
0.7481 |
Intermediate Similarity |
NPD9621 |
Approved |
0.7479 |
Intermediate Similarity |
NPD968 |
Approved |
0.7466 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7464 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7462 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7431 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7431 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7417 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7415 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7415 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7407 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7398 |
Intermediate Similarity |
NPD9377 |
Approved |
0.7398 |
Intermediate Similarity |
NPD821 |
Approved |
0.7398 |
Intermediate Similarity |
NPD9379 |
Approved |
0.7385 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.736 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7357 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7353 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7313 |
Intermediate Similarity |
NPD3179 |
Approved |
0.7313 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7295 |
Intermediate Similarity |
NPD556 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7273 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7266 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7259 |
Intermediate Similarity |
NPD597 |
Approved |
0.7259 |
Intermediate Similarity |
NPD598 |
Approved |
0.7259 |
Intermediate Similarity |
NPD601 |
Approved |
0.7259 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7257 |
Intermediate Similarity |
NPD9365 |
Approved |
0.7254 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7254 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.7246 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7246 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7246 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7239 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7234 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7231 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7226 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7222 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7218 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7218 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7217 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7217 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7214 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7209 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7209 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7209 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7209 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7206 |
Intermediate Similarity |
NPD1136 |
Approved |
0.7206 |
Intermediate Similarity |
NPD1130 |
Approved |
0.7206 |
Intermediate Similarity |
NPD1132 |
Approved |
0.7203 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7183 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7183 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7182 |
Intermediate Similarity |
NPD111 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7181 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7176 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7176 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7155 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7155 |
Intermediate Similarity |
NPD844 |
Approved |
0.7155 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7154 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7154 |
Intermediate Similarity |
NPD9380 |
Clinical (unspecified phase) |
0.7153 |
Intermediate Similarity |
NPD3061 |
Approved |
0.7153 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7153 |
Intermediate Similarity |
NPD3059 |
Approved |
0.7153 |
Intermediate Similarity |
NPD3062 |
Approved |
0.7153 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD940 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1817 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1818 |
Approved |
0.7143 |
Intermediate Similarity |
NPD846 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1819 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1820 |
Approved |
0.7133 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7133 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7132 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7132 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7121 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7121 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7119 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7114 |
Intermediate Similarity |
NPD37 |
Approved |
0.7113 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7105 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7099 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7097 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7094 |
Intermediate Similarity |
NPD288 |
Approved |
0.7092 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7092 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7092 |
Intermediate Similarity |
NPD5763 |
Approved |
0.708 |
Intermediate Similarity |
NPD9295 |
Approved |
0.7071 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7071 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7068 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7067 |
Intermediate Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7059 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD52 |
Approved |
0.7055 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7055 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7054 |
Intermediate Similarity |
NPD9545 |
Approved |
0.705 |
Intermediate Similarity |
NPD5314 |
Approved |
0.7049 |
Intermediate Similarity |
NPD3134 |
Approved |
0.7045 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7042 |
Intermediate Similarity |
NPD7153 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7027 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7021 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.702 |
Intermediate Similarity |
NPD2560 |
Approved |
0.702 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7016 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7015 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7014 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7008 |
Intermediate Similarity |
NPD9299 |
Approved |
0.7007 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7007 |
Intermediate Similarity |
NPD5718 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.6993 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6986 |
Remote Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.6985 |
Remote Similarity |
NPD600 |
Approved |
0.6985 |
Remote Similarity |
NPD596 |
Approved |
0.698 |
Remote Similarity |
NPD4678 |
Approved |
0.698 |
Remote Similarity |
NPD4675 |
Approved |
0.6978 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6978 |
Remote Similarity |
NPD447 |
Suspended |
0.6978 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6974 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6974 |
Remote Similarity |
NPD4965 |
Approved |
0.6974 |
Remote Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD4966 |
Approved |
0.6966 |
Remote Similarity |
NPD5058 |
Phase 3 |
0.6963 |
Remote Similarity |
NPD558 |
Phase 2 |
0.6962 |
Remote Similarity |
NPD7054 |
Approved |
0.6957
|
Remote Similarity |
NPD839 |
Approved |